Who are Standard bismuth quadruple's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-bismuth-quadruple.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Standard bismuth quadruple — Competitive Intelligence Brief

Standard bismuth quadruple (Standard bismuth quadruple) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy / Bismuth-based anti-ulcer agent. Area: Gastroenterology / Infectious Disease.

marketed Antibiotic combination therapy / Bismuth-based anti-ulcer agent Helicobacter pylori (bacterial pathogen) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Standard bismuth quadruple (Standard bismuth quadruple) — Xijing Hospital of Digestive Diseases. Standard bismuth quadruple therapy combines bismuth salts with antibiotics and acid suppression to eradicate Helicobacter pylori infection through multiple mechanisms including direct bacterial toxicity and reduced antibiotic resistance.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard bismuth quadruple TARGET	Standard bismuth quadruple	Xijing Hospital of Digestive Diseases	marketed	Antibiotic combination therapy / Bismuth-based anti-ulcer agent	Helicobacter pylori (bacterial pathogen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy / Bismuth-based anti-ulcer agent class)

Xijing Hospital of Digestive Diseases · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard bismuth quadruple — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-bismuth-quadruple. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab